CZMWY logo

Carl Zeiss Meditec AG (CZMWY) Análisis de Acciones

Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

CZMWY representa a Carl Zeiss Meditec AG, una empresa del sector Healthcare con un precio de $ (capitalización de mercado 0). La acción obtiene una puntuación de 51/100, una calificación moderada basada en 9 KPI cuantitativos.

Ultimo analisis: 16 mar 2026
Puntuación de IA de 51/100

Carl Zeiss Meditec AG (CZMWY) Resumen de Asistencia Médica y Tuberías

CEOAndreas Pecher
Empleados2066
Sede CentralJena, DE
Año de la oferta pública inicial (OPI)2012

Carl Zeiss Meditec AG, a German medical technology company, develops and distributes ophthalmic and microsurgical devices globally. With a strong presence in Europe, the US, and Asia, the company focuses on solutions for diagnosing and treating eye diseases, as well as visualization systems for various surgical disciplines, maintaining a 6.3% profit margin.

Procedencia de los datos | Datos financieros Análisis cuantitativo NASDAQ Análisis: 16 mar 2026

Tesis de Inversión

Carl Zeiss Meditec AG presents a compelling investment case based on its established market position, consistent profitability, and growth opportunities in the medical technology sector. With a P/E ratio of 14.63 and a profit margin of 6.3%, the company demonstrates financial stability. A key value driver is the increasing demand for advanced ophthalmic and microsurgical solutions, fueled by an aging global population and rising healthcare expenditures. The company's strong gross margin of 65.8% indicates efficient operations and pricing power. Ongoing: Continued innovation in product development and expansion into emerging markets are expected to drive revenue growth. Potential: However, investors should be aware of risks related to regulatory changes and competition within the medical device industry.

Basado en las finanzas de FMP y el análisis cuantitativo

Puntos clave

  • Market capitalization of $2.36 billion, reflecting its established position in the medical technology sector.
  • P/E ratio of 14.63, suggesting a reasonable valuation compared to its earnings.
  • Profit margin of 6.3%, indicating consistent profitability in a competitive market.
  • Gross margin of 65.8%, demonstrating efficient operations and strong pricing power.
  • Dividend yield of 2.54%, providing a steady income stream for investors.

Competidores y Pares

Fortalezas

  • Strong brand reputation in the medical technology sector.
  • Comprehensive product portfolio spanning ophthalmic devices and microsurgery.
  • Global presence with a diverse customer base.
  • Consistent profitability and strong gross margins.

Debilidades

  • Reliance on a limited number of key products.
  • Exposure to regulatory changes and healthcare reforms.
  • Potential for product recalls or liability claims.
  • Dependence on third-party distributors in certain markets.

Catalizadores

  • Ongoing: Increasing demand for ophthalmic devices and microsurgical solutions due to an aging global population.
  • Ongoing: Continued innovation in product development and expansion into new markets.
  • Upcoming: Potential regulatory approvals for new medical devices.
  • Ongoing: Strategic partnerships and acquisitions to expand product portfolio and market reach.

Riesgos

  • Potential: Intense competition from established medical device companies.
  • Potential: Technological advancements that could render existing products obsolete.
  • Potential: Economic downturns that could reduce healthcare spending.
  • Ongoing: Fluctuations in currency exchange rates.
  • Ongoing: Regulatory changes and healthcare reforms that could impact profitability.

Oportunidades de crecimiento

  • Growth opportunity 1: Expansion in Emerging Markets: Carl Zeiss Meditec AG has a significant opportunity to expand its presence in emerging markets, particularly in Asia and Latin America. These regions are experiencing rapid growth in healthcare spending and increasing demand for advanced medical technologies. By establishing strategic partnerships and tailoring its product offerings to meet local needs, the company can capture a larger share of these rapidly growing markets. The global market for medical devices is projected to reach $600 billion by 2025, providing a substantial opportunity for growth.
  • Growth opportunity 2: Innovation in Digital Healthcare: The integration of digital technologies into healthcare is transforming the industry, creating new opportunities for companies like Carl Zeiss Meditec AG. By developing innovative digital solutions for remote monitoring, data analytics, and personalized treatment, the company can enhance its product offerings and improve patient outcomes. The digital health market is expected to reach $379 billion by 2024, driven by increasing adoption of telehealth and remote patient monitoring technologies.
  • Growth opportunity 3: Strategic Acquisitions: Carl Zeiss Meditec AG can pursue strategic acquisitions to expand its product portfolio, enter new markets, and enhance its technological capabilities. By acquiring companies with complementary technologies or established market positions, the company can accelerate its growth and strengthen its competitive advantage. The medical device industry is characterized by ongoing consolidation, with companies seeking to expand their reach and capabilities through strategic acquisitions.
  • Growth opportunity 4: Focus on Minimally Invasive Surgery: The trend towards minimally invasive surgical procedures is driving demand for advanced visualization and surgical technologies. Carl Zeiss Meditec AG can capitalize on this trend by developing innovative solutions that enable surgeons to perform complex procedures with greater precision and efficiency. The global market for minimally invasive surgical instruments is projected to reach $42 billion by 2027, driven by increasing adoption of these techniques in various surgical specialties.
  • Growth opportunity 5: Development of Artificial Intelligence (AI) Applications: AI is transforming the healthcare industry, offering new opportunities for improving diagnosis, treatment, and patient care. Carl Zeiss Meditec AG can leverage AI to develop innovative applications for image analysis, surgical planning, and personalized medicine. By integrating AI into its products and services, the company can enhance its competitive advantage and drive growth. The AI in healthcare market is expected to reach $67 billion by 2027, driven by increasing adoption of AI-powered solutions in various healthcare applications.

Oportunidades

  • Expansion in emerging markets with growing healthcare spending.
  • Innovation in digital healthcare and AI applications.
  • Strategic acquisitions to expand product portfolio and market reach.
  • Growing demand for minimally invasive surgical procedures.

Amenazas

  • Intense competition from established medical device companies.
  • Technological advancements that could render existing products obsolete.
  • Economic downturns that could reduce healthcare spending.
  • Fluctuations in currency exchange rates.

Ventajas competitivas

  • Established brand reputation in the medical technology sector.
  • Strong focus on innovation and product development.
  • Global presence with a diverse customer base.
  • Comprehensive product portfolio spanning ophthalmic devices and microsurgery.

Acerca de CZMWY

Founded in 1846 and headquartered in Jena, Germany, Carl Zeiss Meditec AG has evolved into a prominent player in the medical technology sector. The company operates through two primary segments: Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment provides a comprehensive range of products and solutions for the diagnosis and treatment of eye diseases, including systems and consumables for cataract, retinal, and refractive surgeries. These offerings cater to practicing ophthalmologists and optometrists, as well as physicians and surgeons in hospitals and outpatient surgery centers. The Microsurgery segment focuses on visualization solutions for invasive surgical treatments, serving physicians in fields such as ear, nose, and throat, plastic and reconstructive, dental, and spinal surgeries. Carl Zeiss Meditec AG's global presence extends across Europe, the United States, and Asia, reflecting its commitment to serving a diverse customer base with innovative medical technology solutions. As a subsidiary of Carl Zeiss AG, the company leverages a rich heritage of precision engineering and technological advancement to maintain its competitive edge in the medical device market.

Qué hacen

  • Develops and distributes medical technology solutions.
  • Offers products for the diagnosis and treatment of eye diseases.
  • Provides systems and consumables for cataract, retinal, and refractive surgeries.
  • Offers visualization solutions for invasive surgical treatments.
  • Provides solutions for ear, nose, and throat surgeries.
  • Provides solutions for plastic and reconstructive surgeries.
  • Provides solutions for dental and spinal surgeries.

Modelo de Negocio

  • Develops and manufactures ophthalmic devices and microsurgical solutions.
  • Sells products and services to hospitals, outpatient surgery centers, and physicians.
  • Generates revenue through the sale of equipment, consumables, and service contracts.

Contexto de la Industria

Carl Zeiss Meditec AG operates within the medical instruments and supplies industry, a sector characterized by continuous innovation and increasing demand driven by an aging global population and rising healthcare expenditures. The industry is highly competitive, with key players focusing on technological advancements and strategic partnerships to gain market share. Carl Zeiss Meditec AG's focus on ophthalmic and microsurgical solutions positions it within a specialized segment of the broader medical device market, allowing it to cater to specific needs and maintain a competitive edge through its established brand and innovative product portfolio. Competitors include ADDLF (Alcon AG), AHICF (Asahi Intecc Co Ltd), ANSLF (AngioDynamics Inc), BUHPF (Bausch Health Companies Inc), and FLMNF ( ফুলমন টেকনোলজিস লিমিটেড ).

Clientes Clave

  • Practicing ophthalmologists and optometrists.
  • Physicians and surgeons in hospitals.
  • Physicians and surgeons in outpatient surgery centers.
Confianza de la IA: 71% Actualizado: 16 mar 2026

Finanzas

Gráfico e información

Precio de la acción de Carl Zeiss Meditec AG (CZMWY): Price data unavailable

Últimas noticias

Consenso de analistas

Calificación de Consenso

Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para CZMWY.

Objetivos de Precios

Análisis del precio objetivo de Wall Street para CZMWY.

MoonshotScore

51/100

¿Qué significa esta puntuación?

El MoonshotScore califica el potencial de crecimiento de CZMWY en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.

Liderazgo: Andreas Pecher

Unknown

Information on Andreas Pecher's specific background and career history is not available in the provided data. Therefore, a detailed biography cannot be constructed. He is currently managing 2066 employees.

Historial: Due to the lack of available data, it is not possible to provide specific details regarding Andreas Pecher's key achievements, strategic decisions, or company milestones under his leadership.

Información de ADR de Carl Zeiss Meditec AG No patrocinado

An American Depositary Receipt (ADR) like CZMWY represents shares of a non-U.S. company (Carl Zeiss Meditec AG) held by a U.S. depositary bank. CZMWY allows U.S. investors to trade shares of the German company on the OTC market without the complexities of cross-border transactions. Dividends and capital gains are subject to U.S. tax regulations.

  • Ticker del mercado local: CZMW trades on the Frankfurt Stock Exchange in Germany.
  • Nivel de ADR: 1
  • Ratio de ADR: 1:1
  • Ticker del mercado local: CZMW
Riesgo cambiario: As an ADR, CZMWY is subject to currency risk. The value of the ADR can fluctuate based on changes in the exchange rate between the US dollar and the Euro. If the Euro weakens against the dollar, the value of CZMWY may decrease, even if the underlying stock price in Germany remains constant.
Implicaciones fiscales: Dividends paid on CZMWY shares may be subject to foreign dividend withholding tax in Germany. The standard withholding tax rate is unknown. However, a tax treaty between the U.S. and Germany may reduce the withholding tax rate for eligible U.S. investors. It is important to consult with a tax advisor to determine the specific tax implications.
Horario de negociación: The Frankfurt Stock Exchange (CZMW's home market) operates from 9:00 AM to 5:30 PM Central European Time (CET). This translates to 3:00 AM to 11:30 AM Eastern Time (ET). As CZMWY trades on the OTC market in the U.S., its trading hours generally align with the U.S. market hours (9:30 AM to 4:00 PM ET), creating a significant overlap but also periods of non-alignment.

Información del mercado OTC de CZMWY

The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies trading on this tier often have limited financial disclosure and may not meet the listing requirements of major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the potential for limited information and regulatory oversight. These companies are not required to meet minimum financial standards, and may not be current in their reporting.

  • Nivel OTC: OTC Other
  • Estado de divulgación: Unknown
Liquidez: As an OTC-traded stock, CZMWY's liquidity may be limited compared to stocks listed on major exchanges. This can result in wider bid-ask spreads and greater price volatility. Investors may experience difficulty buying or selling large quantities of CZMWY shares without significantly impacting the price. The trading volume and bid-ask spread should be carefully monitored before investing.
Factores de riesgo OTC:
  • Limited financial disclosure and regulatory oversight.
  • Potential for low trading volume and liquidity.
  • Greater price volatility compared to exchange-listed stocks.
  • Risk of fraud or manipulation due to limited scrutiny.
  • Uncertainty regarding the company's long-term viability.
Lista de verificación de diligencia debida:
  • Verify the company's registration and legal status.
  • Obtain and review the company's financial statements (if available).
  • Assess the company's management team and their track record.
  • Research the company's industry and competitive landscape.
  • Evaluate the company's business model and growth prospects.
  • Understand the risks associated with investing in OTC stocks.
  • Consult with a financial advisor before making any investment decisions.
Señales de legitimidad:
  • Established operating history as a subsidiary of Carl Zeiss AG.
  • Presence in the medical technology sector.
  • Availability of information on the company's website.
  • Positive media coverage or industry recognition.
  • Listing on a foreign stock exchange (Frankfurt Stock Exchange).

CZMWY Preguntas Frecuentes sobre Acciones de Healthcare

¿Cuáles son los factores clave para evaluar CZMWY?

Carl Zeiss Meditec AG (CZMWY) actualmente tiene una puntuación IA de 51/100, indicando puntuación moderada. Fortaleza clave: Strong brand reputation in the medical technology sector.. Riesgo principal a monitorear: Potential: Intense competition from established medical device companies.. Esto no es asesoramiento financiero.

¿Qué es el MoonshotScore de CZMWY?

CZMWY actualmente puntúa 51/100 (Grado C) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.

¿Con qué frecuencia se actualizan los datos de CZMWY?

Los precios de CZMWY se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.

¿Qué dicen los analistas sobre CZMWY?

La cobertura de analistas para CZMWY incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.

¿Cuáles son los riesgos de invertir en CZMWY?

Las categorías de riesgo para CZMWY incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Intense competition from established medical device companies.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.

¿Cuál es la relación P/E de CZMWY?

La relación P/E para CZMWY compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.

¿Está CZMWY sobrevalorada o infravalorada?

Determinar si Carl Zeiss Meditec AG (CZMWY) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.

¿Cuál es el rendimiento por dividendo de CZMWY?

Carl Zeiss Meditec AG (CZMWY) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.

Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.

Recursos Oficiales

Análisis actualizado el Puntuación de IA actualizada diariamente
Fuentes de Datos y Metodología
Datos de mercado proporcionados por Financial Modeling Prep y Yahoo Finance. Análisis de IA por algoritmos propietarios de Stock Expert AI. Indicadores técnicos mediante cálculos estándar de la industria. Última actualización: .

Datos proporcionados solo con fines informativos.

Notas de análisis
  • Information is based on available data and may be subject to change.
  • OTC market data may be limited and less reliable than exchange-listed data.
  • AI analysis is pending and may provide additional insights.
Fuentes de datos

Popular Stocks